During the entire lifecycle of their products, pharmaceutical and biotech
companies are increasingly pressured to get the most out of their assets. They
are confronted with numerous challenges at each point of the lifecycle, from
post-trial access to market exit worldwide, all the more because of the rising
recognition of the need to provide patient access to medicines for clinical trials
and both unlicensed and licensed supply.

Adianant is one of the main global players in the specialist management of
ethical, regulatory compliant and efficient solutions that assist pharma and
biotech companies in providing access to medicines.